| abstract |
The present invention provides isolated cell compositions suitable for adoptive immunotherapy, as well as methods of making such cell compositions and methods of treatment using such cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for the target peptide antigen(s). In various embodiments, the composition is predominantly CD8+ T cells, and at least about 20% of the T cells in the composition exhibit a central or effector memory phenotype, resulting in a robust, long-lasting adoptive therapy from a natural T cell repertoire that has undergone natural selection. to provide. |